Vyome Holdings, Inc. (HIND)
NASDAQ:HIND
Want to see HIND full AI Analyst Report?
HIND Stock Chart & Stats
$5.42
--
Market closed
$5.42
--
Day’s Range― - ―
52-Week Range$1.75 - $46.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)28.88K
Market Cap
$13.76M
Enterprise Value$6.82M
Total Cash (Recent Filing)$4.98M
Total Debt (Recent Filing)$31.26K
Price to Earnings (P/E)―
Beta1.31
Next Earnings
May 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-29.21
Shares Outstanding7,018,528
10 Day Avg. Volume19,649
30 Day Avg. Volume28,879
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.04
Price to Sales (P/S)23.26
P/FCF Ratio-1.98
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue2.81
Enterprise Value/Gross Profit5.17
Enterprise Value/Ebitda-2.49
Forecast
1Y Price Target
$11.50Price Target Upside112.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 2 Clinical Data (VT-1953)Positive Phase 2 investigator-initiated results materially de-risk VT-1953 as a treatment for malignant fungating wounds. Efficacy, tolerability and patient-reported benefit create a credible path for further development, potential licensing or partnership and durable commercial optionality in an underserved niche.
Strategic AI HR Acquisition (Livechain/Humanyze)The Humanyze asset integration creates a distinct, non-biotech growth avenue with IP and product-market fit in enterprise HR analytics. Structurally this diversifies revenue pathways, allows independent capital-raising for Livechain and can materially reduce reliance on clinical timelines for value creation.
Low Leverage On Balance SheetLow debt reduces solvency and interest burdens, preserving financial flexibility to fund trials, business development or restructurings. For a cash-burning biotech, limited leverage lowers near-term default risk and provides optionality to pursue strategic initiatives without immediate refinancing pressure.
Bears Say
Revenue Collapse In 2025A dramatic revenue decline erodes the company’s commercial base and undermines internal funding for R&D and operations. Such structural revenue deterioration increases dependency on external financing, weakens bargaining power with partners, and raises execution risk over the medium term.
Persistent Negative Cash FlowChronic cash burn constrains runway and forces recurrent capital raises or asset sales. Persistent negative operating and free cash flow limit the firm’s ability to self-fund trials or commercialization, increasing dilution risk and making long-term planning dependent on successful financing or partnerships.
Deep Unprofitability And Equity VolatilitySustained net losses and episodes of negative equity reflect weak returns and capital instability. This undermines shareholder value persistence, can complicate recruiting/partnering, and elevates the probability of dilutive financings or restructuring that materially affect long-term strategic execution.
Vyome Holdings News
HIND FAQ
What was Vyome Holdings, Inc.’s price range in the past 12 months?
Vyome Holdings, Inc. lowest stock price was $1.75 and its highest was $46.50 in the past 12 months.
What is Vyome Holdings, Inc.’s market cap?
Vyome Holdings, Inc.’s market cap is $13.76M.
When is Vyome Holdings, Inc.’s upcoming earnings report date?
Vyome Holdings, Inc.’s upcoming earnings report date is May 26, 2026 which is in 21 days.
How were Vyome Holdings, Inc.’s earnings last quarter?
Vyome Holdings, Inc. released its earnings results on Mar 26, 2026. The company reported -$0.207 earnings per share for the quarter, beating the consensus estimate of -$0.47 by $0.263.
Is Vyome Holdings, Inc. overvalued?
According to Wall Street analysts Vyome Holdings, Inc.’s price is currently Undervalued.
Does Vyome Holdings, Inc. pay dividends?
Vyome Holdings, Inc. does not currently pay dividends.
What is Vyome Holdings, Inc.’s EPS estimate?
Vyome Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vyome Holdings, Inc. have?
Vyome Holdings, Inc. has 7,018,528 shares outstanding.
What happened to Vyome Holdings, Inc.’s price movement after its last earnings report?
Vyome Holdings, Inc. reported an EPS of -$0.207 in its last earnings report, beating expectations of -$0.47. Following the earnings report the stock price went down -3.084%.
Which hedge fund is a major shareholder of Vyome Holdings, Inc.?
Currently, no hedge funds are holding shares in HIND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vyome Holdings, Inc.
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.
HIND Stock 12 Month Forecast
Average Price Target
$11.50
▲(112.18% Upside)
Technical Analysis
Ownership Overview
6.49% Insiders
0.23% Mutual Funds
― Other Institutional Investors
93.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---